贝那普利联合黄葵对慢性肾小球肾炎的治疗效果及安全性评价

Therapeutic Effect and Safety Evaluation of Benazepril Combined withAbelmosk in the Treatment of Chronic Glomerulonephritis

目的:评价探究贝那普利联合黄葵对慢性肾小球肾炎的治疗效果及安全性。方法:选择92例来某院接受治疗的慢性肾小球肾炎患者进行研究观察,按照抛硬币的分组方式均匀分成两组,即为对照组(贝那普利治疗)和观察组(贝那普利联合黄葵)各46例,对比两组患者的疗效、肾功能指标变化。结果:观察组患者的尿蛋白定量、尿素氮以及血清肌酐水平均显著低于对照组,组间对比差异明显;观察组患者药物治疗后的疗效显著高于对照组,组间差异有统计学意义,P<0.05。结论:临床治疗慢性肾小球肾炎选用黄葵联合贝那普利的药物价值高,对患者肾功能的改善效果明显,具有积极的临床应用价值。

Objective:To evaluate the therapeutic effect and safety of benazepril combined with abelmosk in the treatment of chronic glomerulonephritis.Methods:A total of 92patients with chronic glomerulonephritis treated in a hospital were selected and divided into two groups according to the grouping of coin toss,namely the control group(benazepril treatment)and the observation group(benazepril combined with abelmosk),46patients in each group.The efficacy and renal function indexes of the two groups were compared.Results:The urine protein,urea nitrogen and serum creatinine levels in the observation group were significantly lower than those in the control group.The difference between the groups was significant.The therapeutic effect of the observation group was significantly higher than that of the control group.The difference between the groups was statistically significant,P<0.05.Conclusion:The clinical value of benazepril combined with abelmosk in the treatment of chronic glomerulonephritis is high,and it has obvious effect on the improvement of renal function,with positive clinical application value.